Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Commentary|Articles|July 21, 2026
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
Author(s)Tyler Garman, MD
Fact checked by: Hannah Clarke, Cheney Gazzam Baltz
Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG-naive NMIBC.
Advertisement
Advertisement
As ongoing BCG shortages continue to challenge the management of high-risk non–muscle-invasive bladder cancer (NMIBC), interest has grown in alternative first-line intravesical treatment strategies. Updated findings from the phase 2 GEMDCE trial (NCT04386746) of first-line intravesical gemcitabine and docetaxel (gem/doce) showed durable 3-year high-grade recurrence-free survival, no progression during treatment, and a manageable safety profile in patients with BCG-naive high-risk NMIBC.1
Related to this article
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
A decision is expected by the fourth quarter of 2026.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Eugene Cone, MD, discusses the impact of ongoing BCG supply challenges and the potential role of alternative and recombinant strains for NMIBC care.
All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.
Advertisement
Advertisement